Bactiguard secures financing

Bactiguard has entered a credit facility agreement of 130 million SEK in total. Combined with the company’s cash position, the credit facility secures the refinancing of Bactiguard’s bond loan, which matures in December 2016.

During the autumn, Bactiguard has been working on securing the refinancing of its bond loan. The income received in connection with the additional order from
C.R. Bard has enabled the company to repurchase further bonds in the market and reduce the outstanding loan to 139 million SEK. Taking the cash position of 48.8 million SEK into account, the company’s net debt amounts to 91.6 million SEK as per 30 September. Today a credit facility of 130 million SEK in total was signed, which combined with the company’s cash position secures the refinancing of the bond loan when it expires in December 2016.

This is information that Bactiguard Holding AB (publ) is required to publish in compliance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on 10 November 2015, at 16.00.

For further information, please contact:
Cecilia Edström, Director of Sales & New business; mobile +46 72 226 23 28

About Bactiguard
Bactiguard is a Swedish medtech company with a mission of preventing healthcare associated infections, reducing the use of antibiotics and saving lives by developing and supplying infection prevention solutions for the healthcare industry. The company’s patented coating prevents healthcare associated infections by reducing bacterial adhesion and growth on medical devices. Bactiguard®-coated urinary catheters are market leading in the US and Japan, and in recent years the company has developed its own product portfolio of catheters for the urinary and respiratory tract and the blood stream. Bactiguard is currently in a strong expansion phase, focused on new markets in the Europe, Middle East, Asia, South America and Southern Africa. The company has market presence in some 50 countries and has about 60 employees. Its headquarters is located in Stockholm and production facilities in Sweden and Malaysia. Bactiguard is listed on Nasdaq Stockholm. Read more about Bactiguard at

About Us

Bactiguard is a Swedish medtech company with a global presence, offering a solution that prevents healthcare associated infections caused by medical devices. By preventing infections, we contribute to a reduced use of antibiotics and the spread of multi-resistant bacteria, which is a growing problem worldwide. We save lives, increase patient safety and significantly reduce the cost for the healthcare and society. Our technology is well-proven, safe and tissue friendly and consist of a thin layer of noble metals that prevents bacterial growth. The coating can be applied on almost all medical devices. Bactiguard-coated urinary catheters are market leading in the US and Japan and the company has also its own product portfolio consisting of foley catheters, central venous catheters and endotrachealtubes. Bactiguard is a growth company, focused on markets in Europe, Middle East, Asia and Latin America. The company has about 70 employees worldwide, mainly at the headquarters in Stockholm and the production facility in Malaysia and is listed on Nasdaq Stockholm. Read more about Bactiguard at